{"entity":{"id":"canariabio","kind":"company","name":"CanariaBio","aka":["OncoQuest","OncoQuest Pharmaceuticals","카나리아바이오"],"tldr":"CanariaBio is a South Korean biotech that took over oregovomab, an antibody against the ovarian cancer marker CA-125 that is given with chemotherapy to prime an immune response against the tumour.","summary":"CanariaBio acquired the oregovomab programme from OncoQuest of Edmonton, Canada. Oregovomab (MAb-B43.13) binds circulating CA-125 and, given at the same time as carboplatin and paclitaxel, forms immune complexes that induce CA-125-specific T-cell responses. After a phase 2 trial suggested longer progression-free survival, the phase 3 FLORA-5 trial in newly diagnosed advanced ovarian cancer read out in 2024 without meeting its primary endpoint.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["oregovomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seongnam","country":"KR","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/canariabio/","neighbours":{"drug":[{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/"}],"trial":[{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","route":"/trials/nct05335993/"},{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct04938583/"},{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","route":"/trials/nct04498117/"},{"id":"nct05605535","kind":"trial","name":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","route":"/trials/nct05605535/"}]}}